Table 3.
Risk factors related to myocardial hypertrophy, systolic function and myocardial fibrosis.
| LVH+ (n = 16) | LVH− (n = 45) | IVSH+ (n = 17) | IVSH− (n = 44) | LVSD+ (n = 5) | LVSD− (n = 56) | RVSD+ (n = 6) | RVSD− (n = 55) | MCF+ (n = 9) | MCF− (n = 52) | |
|---|---|---|---|---|---|---|---|---|---|---|
| GH (ng/ml) | 56.1 ± 72.6 | 33.0 ± 38.5 | 47.5 ± 68.0 | 35.8 ± 41.7 | 6.0 ± 2.3 | 42.0 ± 51.3 | 10.7 ± 8.1 | 42.2 ± 51.8 | 52.4 ± 81.8 | 36.8 ± 43.2 |
| GH nadir (ng/ml) | 47.2 ± 65.2 | 21.4 ± 26.6 | 40.0 ± 62.3 | 23.7 ± 29.4 | 5.0 ± 1.9 | 30.3 ± 42.6 | 9.2 ± 7.7 | 30.3 ± 43.0 | 44.1 ± 72.6 | 25.5 ± 33.7 |
| IGF-1 (ng/ml) | 887.9 ± 249.0 | 899.5 ± 258.3 | 912.7 ± 299.5 | 890.2 ± 237.5 | 855.2 ± 420.0 | 900.1 ± 239.4 | 963.8 ± 381.5 | 889.1 ± 240.0 | 859.0 ± 214.7 | 902.9 ± 261.3 |
| Age (years) | 47.7 ± 12.5 | 41.2 ± 13.6 | 50.8 ± 14.4∗ | 39.9 ± 12.0 | 58.0 ± 8.0∗ | 41.5 ± 13.0 | 50.0 ± 10.8 | 42.2 ± 13.7 | 48.8 ± 9.9 | 42.0 ± 14.0 |
| Body mass index (kg/m2) | 28.2 ± 3.6∗ | 25.4 ± 3.6 | 28.0 ± 3.7∗ | 25.4 ± 3.6 | 28.7 ± 3.1 | 25.9 ± 3.8 | 31.3 ± 5.8∗ | 25.6 ± 3.1 | 28.7 ± 3.3∗ | 25.7 ± 3.7 |
| Disease duration (months) | 102 ± 61.7∗ | 70.1 ± 53.6 | 93.9 ± 50.1 | 72.5 ± 59.0 | 81.6 ± 41.0 | 78.2 ± 58.5 | 144.0 ± 56.3∗ | 71.3 ± 52.8 | 101.3 ± 72.3 | 74.5 ± 53.9 |
| Arterial hypertension (yes/no)/(%) | 6/10, 37.5%∗ | 5/40, 11.1% | 6/11, 35.3% | 5/39, 11.4% | 3/2, 60.0%∗ | 8/48, 14.3% | 4/2, 66.7% | 7/48, 12.7% | 4/5, 44.4% | 7/45, 13.5% |
| Diabetes mellitus (yes/no)/(%) | 4/12, 25.0% | 4/41, 8.9% | 4/13, 23.5% | 4/40, 9.1% | 2/3, 40.0% | 6/50, 10.7% | 3/3, 50.0%∗ | 5/50, 9.1% | 1/8, 11.1% | 7/45, 13.5% |
| Hyperlipemia (yes/no)/(%) | 1/15, 6.3% | 7/38, 15.6% | 2/15, 11.8% | 6/38, 13.6% | 0/5, 0.0% | 8/48, 14.3 | 0/6, 0.0% | 8/47, 14.5% | 1/8, 11.1% | 7/45, 13.5% |
| Smoking habit (yes/no)/(%) | 6/10, 37.5% | 6/39, 13.3% | 6/11, 35.3% | 6/38, 13.6% | 2/3, 40.0% | 10/46, 17.9% | 3/3, 50.0% | 9/46, 16.4% | 3/6, 33.3% | 9/43, 17.3% |
GH, growth hormone; IGF-1, insulin-like growth factor 1; LVH, left ventricular hypertrophy; IVSH, interventricular septum hypertrophy; LVSD, left ventricular systolic dysfunction; RVSD, right ventricular systolic dysfunction; MCF, myocardial fibrosis. Values are presented as frequencies (%) and the mean ± standard deviation. ∗It means the difference between male and female patients is significant (p < 0.05).